Highlights Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
22.98 ^USD	-1.63%		+2.00%	-23.32%

05-06	Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	04-02	CI
Rocket Pharmaceuticals Q4 Loss Narrows	02-26	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-25	CI
North American Morning Briefing : S&P 500 Futures -2-	02-23	DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	02-13	MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi	02-13	DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	02-13	CI
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-05	CI
Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	02/10/23	CI
Rocket Pharmaceuticals, US FDA Agree on Design of Mid-Stage Trial of Genetic Disorder Drug Candidate	13/09/23	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Rocket Pharmaceuticals Says Gene Therapy Candidate Received US FDA Fast Track, Orphan Drug Designations	08/06/23	MT
Rocket Pharmaceuticals Gets Priority Medicines Designation for RP-A501 Gene Therapy for Danon Disease in Europe	31/05/23	MT
Rocket Pharmaceuticals Receives European Medicines Agency Priority Medicines Designation for RP-A501 Gene Therapy for Danon Disease	31/05/23	CI
Rocket Pharmaceuticals Says US FDA Cleared Investigational New Drug Application for Heart Disease Candidate RP-A601	09/05/23	MT
Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy	09/05/23	CI
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Rocket Pharmaceuticals Posts Wider Q4 Loss	27/02/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Highlights

Filters